ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
BB Biotech AG (PK)

BB Biotech AG (PK) (BBAGF)

48.00
0.00
( 0.00% )
Updated: 12:04:13

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
48.00
Bid
40.53
Ask
45.53
Volume
-
0.00 Day's Range 0.00
43.65 52 Week Range 57.70
Market Cap
Previous Close
48.00
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
10
Shares Outstanding
54,846,000
Dividend Yield
-
PE Ratio
-12.74
Earnings Per Share (EPS)
-3.77
Revenue
530k
Net Profit
-206.61M

About BB Biotech AG (PK)

Sector
Finance Services
Industry
Finance Services
Headquarters
Kuesnacht, Che
Founded
-
BB Biotech AG (PK) is listed in the Finance Services sector of the OTCMarkets with ticker BBAGF. The last closing price for BB Biotech (PK) was $48. Over the last year, BB Biotech (PK) shares have traded in a share price range of $ 43.65 to $ 57.70.

BB Biotech (PK) currently has 54,846,000 shares outstanding. The market capitalization of BB Biotech (PK) is $2.63 billion. BB Biotech (PK) has a price to earnings ratio (PE ratio) of -12.74.

BBAGF Latest News

Support For Actelion Melts As BB Biotech Reduces Stake

Support for Actelion Ltd (ATLN.VX) has melted further, as long-time investor BB Biotech (BION.EB) continued to cut its stake in Europe's largest biotech ahead of a key investor meeting next month...

2nd UPDATE: Biotech Actelion Gets Lift On M&A, Shakeup Hopes

Switzerland's Actelion Ltd (ATLN.VX) drew investor interest Friday on hopes a shakeup of the company's top brass could pave the way for a takeover of Europe's largest biotech. Shares in the group...

UPDATE: Biotech Actelion Gets Lift On Takeover, Shakeup Hopes

Switzerland's Actelion Ltd (ATLN.VX) drew investor attention Friday amid hopes that a shakeup of the company's top brass could pave the way for a takeover of Europe's largest biotech company...

2nd UPDATE: Actelion: Tracleer Misses Main Goal In IPF Study

Swiss biotech Actelion Ltd.'s (ATLN.VX) shares slide Monday on news it will shelve development of its key drug Tracleer to treat a deadly lung disease, disappointing investors who had high hopes...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
12004848481048CS
26-0.05-0.10405827263348.0548.0546.511746.6440529CS
524.359.9656357388343.6557.743.6511048.83272232CS
156-33.5203-41.118960553481.520382.443.6549356.26396096CS
260-12.18-20.239282153560.1897.443.6529660.64883727CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TMPOQTempo Automation Holdings Inc (CE)
$ 0.0068
(679,900.00%)
607
JUVAFJuva Life Inc (CE)
$ 0.003
(299,900.00%)
78.81k
SPRNSupernova Energy Inc (CE)
$ 0.0002
(19,900.00%)
100
SIRCSolar Integrated Roofing Corporation (PK)
$ 0.0001
(9,900.00%)
9.52M
JRJCYChina Finance Online Company Ltd (CE)
$ 0.0001
(9,900.00%)
598
ROYERoyal Energy Resources Inc (CE)
$ 0.000001
(-100.00%)
2.8k
ZHCLFZenith Capital Corporation (CE)
$ 0.000001
(-100.00%)
12.18k
AHELFAuscan Resources Inc (CE)
$ 0.000001
(-100.00%)
100
RQHTFReliq Health Technologies Inc (CE)
$ 0.0001
(-99.75%)
2.5k
ATHXQAthersys Inc New (CE)
$ 0.000001
(-99.00%)
54.95k
RDARRaadr Inc (PK)
$ 0.00035
(0.00%)
137.21M
ICNMIcon Media Holdings Inc (PK)
$ 0.0004
(0.00%)
106.84M
GRLFGreen Leaf Innovations Inc (PK)
$ 0.0001
(0.00%)
72.91M
HMBLHUMBL Inc (PK)
$ 0.0002
(33.33%)
65.54M
HCMCHealthier Choices Management Corporation (PK)
$ 0.000001
(0.00%)
54.2M

Discussion

View Full Feed
flipper44 flipper44 3 minutes ago
BTW: Yescarta
The FDA updated the approval for Yescarta (axicabtagene ciloleucel) in April 2022 to allow it to be used as a second-line treatment. This was the first time a CAR T-cell therapy was approved for use as a second-line treatment.

In other words, not SOC.
NWBO
BIOCHEMUP BIOCHEMUP 3 minutes ago
10K 0.002
10K 0.0004
RSPI
TrendTrade2016 TrendTrade2016 3 minutes ago
TGRP GETTING SMOKED...WARNED
TGRP
gfp927z gfp927z 4 minutes ago
>>> Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium


PR Newswire

September 24, 2024


https://finance.yahoo.com/n
ACXP
RIGATONI RIGATONI 4 minutes ago
Looks like they recently terminated their offering...

RAADR, INC. (Form: 1-Z, Received: 09/17/2024 12:39:42) (otcmarkets.com)


certifies that it meets all of the conditions for termination of Regulation A reporting specified in
jedijazz jedijazz 4 minutes ago
$XXII BIG NEWS: $XXII 22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume
CMO customer adds to previously announced cigarette export business with combined volume significantly adding to profitability

Mocksville, North Carolina--(Newsfile Corp. -
XXII
jedijazz jedijazz 4 minutes ago
$XXII BIG NEWS: $XXII 22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume
CMO customer adds to previously announced cigarette export business with combined volume significantly adding to profitability

Mocksville, North Carolina--(Newsfile Corp. -
XXII
Monksdream Monksdream 4 minutes ago
FAAS 10 day hourly
https://investorshub.advfn.com/uimage/uploads/2024/9/25/gwcrrIMG_2125.gif
FAAS
Petroleum2024 Petroleum2024 4 minutes ago
What did hkd do? What's your price target for xhg? Thanks
XHG
Rainer Rainer 4 minutes ago
nice volume
RDAR
MartinLutherKing MartinLutherKing 4 minutes ago
Go big or go home
RNAZ
misanthrope misanthrope 4 minutes ago
What are your expectations?

Regarding financials, don't expect any until the next annual report is due - BIEL no longer files quarterly reports. Regarding news - there likely isn't anything KW is willing or able to report. She has stated when she has news that she can release she
BIEL
DawgTrading DawgTrading 4 minutes ago
Ill take a look around and hunt some down.
CBMJ
TRIPLE_ZERO_SEVEN TRIPLE_ZERO_SEVEN 4 minutes ago
Claims that it's hidden and the TA doesn't even know about it yet. He also claims inside information of a 1 for 2000 reverse split coming. Been claiming these things for at least a year now.
AAPJ
learningcurve2020 learningcurve2020 4 minutes ago
Btw, I hope I'm wrong in this one because I thought their T product was on the right track. But it feels to me like everything is being gutted.
MRKR
nyt nyt 4 minutes ago
They must've reconsidered... lololol

Some here sound as tho they're
HYPNOTIZED
VPLM
MartinLutherKing MartinLutherKing 4 minutes ago
RNAZ On the nasdaq big time brother,
RNAZ
ElectricJester54 ElectricJester54 4 minutes ago
I don't imagine it will hit a dollar off the bat from what I have read from other posts on here, maybe a couple years from now as the merging business grows and gains more attention. I think the realistic figures I have seen if I receall correctly are around like 0.25 per share, which is still a ton
ZHUD
double_m double_m 5 minutes ago
Good question, but I doubt it. If you follow the cycle, he usually gets issued his shares towards the bottom of the price fall off, and some time before announcing a SH meeting via 14A. Those shares are used to control the vote and aren't sold until after the RS. It's a continuous cycle. If you reme
MULN
docsetc docsetc 5 minutes ago
With Chandra's evasive and dispassionate answers today on 'X', I'm inclined to agree on all points. He could actually be uniting all shareholders, patient and incensed right now, for a huge Adnexus launch, but so far nothing that even remotely resembles true leadership or shareholder interests from
ENZC
TrendTrade2016 TrendTrade2016 5 minutes ago
OUCH...YOU WERE WARNE ABOUT THE TOP RINSE...RUG PULL WITH NO WEEKLY TREND
MONI
blackhawks blackhawks 5 minutes ago
But she doesn't lie more than the Orange Felon so, as usual, no f'ing point for you.
alwayswatching1 alwayswatching1 5 minutes ago
We are all amariaddicts. Otherwise why in the world would any of us still be here. Except of course our beloved paid bashers and those bitter souls who sold for epic losses.
AMRN
manibiotech manibiotech 5 minutes ago
In 2023, several cancer and oncology drugs were approved by the FDA. Here are some notable examples:

1. **Epkinly (epcoritamab-bysp)**
Approved on May 19, 2023, Epkinly is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymp
NWBO
oldman69 oldman69 5 minutes ago
Good job trading 101!
DJT

Your Recent History

Delayed Upgrade Clock